MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview With Martyn Thomas, MD
An expert on valvular repair discusses the current state of FDA approval for TAVI, valvular replacement devices, and why he finds interventional cardiology to be such an exciting field to work in.
TAVI With the Edwards Sapien Valve
An update on the latest trial data and the future of aortic valve technology.
By Martyn Thomas, MD, FRCP
The FDA Panel Meeting to Discuss Transcatheter Aortic Valve Implantation
A first-hand European perspective.
Postmarket Data Presented for Edwards Sapien Valve
May 25, 2010—Edwards Lifesciences (Irvine, CA) announced that Martyn Thomas, MD, presented 1-year data from the company's SOURCE registry at the EuroPCR 2010 conference in Paris.
One-Year TAVI Outcomes Published for Edwards' SOURCE Registry
July 11, 2011—Martyn Thomas, MD, et al published 1-year outcomes of Cohort 1 in the European SOURCE Registry online ahead of print in Circulation.
One-Year Postmarket Data Presented for Edwards Sapien Transcatheter Heart Valve
Published Studies Focus on TAVI
November 22, 2010—Transcatheter aortic valve implantation (TAVI) is the focus of the current issue of the Journal of the American College of Cardiology: Cardiovascular Interventions, in which Martyn Thomas, MD, reviewed the global experience with percutaneous aortic valve replacement (2010;3:1103–1109).
Aortic and Mitral Valves
By Ted E. Feldman, MD, FSCAI
Early Humanitarian-Use Procedures With Edwards' Fortis Mitral Valve Reviewed
May 20, 2014—Edwards Lifesciences announced that details about the first-in-human experience with the company’s Fortis mitral transcatheter heart valve were presented at the EuroPCR 2014 congress being held in May 20–23, in Paris, France.
First Human Implantations Performed With Edwards' Fortis Mitral Transcatheter Valve System
March 6, 2014—Edwards Lifesciences Corporation (Irvine, CA) announced that the first three human implantations of the company’s Fortis mitral transcatheter heart valve were successfully performed via a transapical approach in February and March by the heart team at St.
Postmarket SOURCE Registry Data Show Successful 1-Year Outcomes for Edwards Sapien Valve
May 20, 2011—Edwards Lifesciences Corporation (Irvine, CA) announced that data from the postmarket European SOURCE registry studying the first 2 years of commercialization of the Edwards Sapien valve were presented at the EuroPCR 2011 conference in Paris.
CONFERENCE COVERAGE: EuroPCR
Edwards SOURCE Registry Presented for Sapien Valve May 20, 2009—At the EuroPCR conference in Barcelona, Spain, Edwards Lifesciences Corporation (Irvine, CA) announced the results from the SOURCE serial registry, its first postmarket study of consecutively enrolled Edwards Sapien transcatheter aortic valve patients.
Chief Medical Editor's Page: DES Evolution
BMJ Publication Questions Safety and Cost-Effectiveness of TAVI, Quality of European and US Regulatory Processes
Chief Medical Editor's Page: Transcatheter Valve Update
Cellular and Molecular Imaging of Vulnerable Plaque
The potential of optical coherence tomography.
By Dat Do, MD; Thomas E. Milner, PhD; and Marc D. Feldman, MD
The Next Wave of LAA Occlusion Technologies
Interventional stroke prevention in patients with atrial fibrillation.
By Martin W. Bergmann, MD, FESC
Sapien Valve: Past, Present, and Future
A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement.
By Ravinder Singh Rao, MD; Hersh Maniar, MD; and Alan Zajarias, MD
